Triumph Capital Management’s Biogen BIIB Stock Holding History

Triumph Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216	Hold	1	–	–	﹤0.01%	1798
2026 Q1	$183	Buy	+1	New	+$184	﹤0.01%	1770

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Triumph Capital Management's BIIB Position: Q2 2026 in Review

Triumph Capital Management held its Biogen (BIIB) position steady in Q2 2026 at 1 share worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Triumph Capital Management first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Triumph Capital Management held 1 share of Biogen worth $216 as of Q2 2026.
Triumph Capital Management left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1798 holding.
Triumph Capital Management first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.